BRPI0412329A - dispersão sólida de tacrolimus e método de processar a mesma - Google Patents

dispersão sólida de tacrolimus e método de processar a mesma

Info

Publication number
BRPI0412329A
BRPI0412329A BRPI0412329-8A BRPI0412329A BRPI0412329A BR PI0412329 A BRPI0412329 A BR PI0412329A BR PI0412329 A BRPI0412329 A BR PI0412329A BR PI0412329 A BRPI0412329 A BR PI0412329A
Authority
BR
Brazil
Prior art keywords
tacrolimus
processing
solid
solid dispersion
same
Prior art date
Application number
BRPI0412329-8A
Other languages
English (en)
Inventor
Hee-Jong Shin
Jong-Lae Lim
Min-Hyo Ki
Ji-Hun Yun
Original Assignee
Chong Kun Dang Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharm Corp filed Critical Chong Kun Dang Pharm Corp
Publication of BRPI0412329A publication Critical patent/BRPI0412329A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"DISPERSãO SóLIDA DE TACROLIMUS E MéTODO DE PROCESSAR A MESMA". A presente invenção se refere ao veículo da dispersão sólida de tacrolimus, o qual é preparado através de uso de um tensoativo sólido tendo uma propriedade de valor de HLB maior do que ou igual a cerca de 7. O tensoativo desempenha uma função de um veículo e uma função de um intensificador de dissolução, simultaneamente. Como um resultado, a taxa de dissolução do tacrolimus é aperfeiçoada e a capacidade de absorção oral e a biodisponibilidade podem ser aumentada em virtude da rápida liberação de droga.
BRPI0412329-8A 2003-07-09 2004-07-09 dispersão sólida de tacrolimus e método de processar a mesma BRPI0412329A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030046550 2003-07-09
PCT/KR2004/001684 WO2005004848A1 (en) 2003-07-09 2004-07-09 The solid dispersion of tacrolimus

Publications (1)

Publication Number Publication Date
BRPI0412329A true BRPI0412329A (pt) 2006-09-05

Family

ID=36587202

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412329-8A BRPI0412329A (pt) 2003-07-09 2004-07-09 dispersão sólida de tacrolimus e método de processar a mesma

Country Status (9)

Country Link
US (1) US20060177500A1 (pt)
EP (1) EP1641437A4 (pt)
JP (1) JP2007527383A (pt)
KR (1) KR100486016B1 (pt)
CN (1) CN1819817A (pt)
BR (1) BRPI0412329A (pt)
MX (1) MXPA06000370A (pt)
NO (1) NO20060631L (pt)
WO (1) WO2005004848A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2376238T3 (es) * 2003-08-29 2012-03-12 Veloxis Pharmaceuticals A/S Composiciones de liberación modificada comprendiendo tacrolimus.
US7994214B2 (en) 2003-08-29 2011-08-09 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
KR100711220B1 (ko) * 2005-06-14 2007-04-24 삼천당제약주식회사 타크로리무스를 함유하는 경구용 조성물 및 그의 제조방법
KR100693461B1 (ko) * 2005-07-29 2007-03-12 동국제약 주식회사 마크로라이드계 항생물질을 유효성분으로 함유하는약제학적 조성물 및 이의 제조방법과, 상기 약제학적조성물을 함유하는 서방성 제제
MXPA05010457A (es) * 2005-09-28 2007-03-27 Fernando Ahumada Ayala Preparacion para el tratamiento de enfermedades inflamatorias de la piel, que contiene tacrolimus.
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
WO2008033023A2 (en) * 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture
CA2664315C (en) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
PL2167033T4 (pl) 2007-05-30 2018-08-31 Veloxis Pharmaceuticals A/S Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
ES2591352T3 (es) 2010-02-17 2016-11-28 Veloxis Pharmaceuticals A/S Composición de tacrolimus estabilizada
KR20130028824A (ko) * 2011-09-09 2013-03-20 주식회사 삼양바이오팜 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법
ES2600465T3 (es) 2012-05-07 2017-02-09 Echo Pharmaceuticals B.V. Granulado que contiene cannabinoide, método para su producción y unidad de dosificación oral que comprende tal granulado
CN104415054A (zh) * 2013-08-20 2015-03-18 哈药集团三精制药股份有限公司 一种速释复方氨酚烷胺片的制备方法
CN110639020B (zh) * 2019-08-15 2022-07-08 浙江工业大学 一种固体分散体基质及其制备方法和应用
CN113577032A (zh) * 2021-08-27 2021-11-02 国药集团川抗制药有限公司 他克莫司固体分散体的制备方法、速释药物组合物和应用
WO2025220686A1 (ja) * 2024-04-16 2025-10-23 中外製薬株式会社 ペプチド、糖脂肪酸エステル構造を有する界面活性剤及び（メタ）アクリル酸系ポリマーを含む医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
CZ267796A3 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
ZA9710927B (en) * 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
JP4221762B2 (ja) * 1997-04-11 2009-02-12 アステラス製薬株式会社 医薬組成物
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
US7994214B2 (en) * 2003-08-29 2011-08-09 Lifecycle Pharma A/S Solid dispersions comprising tacrolimus

Also Published As

Publication number Publication date
US20060177500A1 (en) 2006-08-10
EP1641437A4 (en) 2009-06-03
EP1641437A1 (en) 2006-04-05
WO2005004848A1 (en) 2005-01-20
MXPA06000370A (es) 2006-03-28
NO20060631L (no) 2006-04-05
KR100486016B1 (ko) 2005-04-29
KR20050007173A (ko) 2005-01-17
JP2007527383A (ja) 2007-09-27
CN1819817A (zh) 2006-08-16

Similar Documents

Publication Publication Date Title
WO2003066005A3 (en) Ansamycins having improved pharmacological and biological properties
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
IL216579A0 (en) Aminocyclohexyl ether derivatives and pharmaceutical compositions containing the same
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
PT1318791E (pt) Composicao farmaceutica semi-solida de isotretinoina
PE20040499A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
WO2004035013A3 (en) Process for dissolving lipophilic compounds, and cosmetic composition
BR9808581A (pt) Estabilização de benzimidazóis sensìveis a ácido com combinações de aminoácido/ciclodextrina
WO2003028650A3 (en) Benzimidazolidinone derivatives as muscarinic agents
BR9807974A (pt) Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma
DE602006013622D1 (de) Steroids und anwendungen davon
CY1109265T1 (el) Συνθεσεις που συμπεριλαμβανουν δροσπιρενονη μοριακα διασπαρμενη
BR0112461A (pt) Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
DK1274401T3 (da) Stabile farmaceutiske sammensætninger indeholdende 7-substituerede-3,5-dihydroxyheptansyrer eller 7-substituerede-3,5-dihydroxyheptensyrer
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
NO20060631L (no) Fast dispersjon av takrolimus
PT1368041E (pt) Composicao aquosa de anfotericina
BRPI0413927B8 (pt) composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
CY1108145T1 (el) Σταθερες συνθεσεις για παρεντερικη χορηγηση
BR9900114A (pt) Composições de ciclodextrina.
AU2002240362A1 (en) Stabilizing compositions comprising at least two anionic associative polymers, their use for stabilization of non-solid compositions, and compositions comprising at least one stabilizing composition
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
WO2002069720A3 (en) Biopesticide compositions
ATE286893T1 (de) 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.